PRKAA2 and hyperlipidemia: These results indicate that metformin can activate AMPK-ATF1-M2-like pathways in macrophages to inhibit AS in hyperlipidemia mice, and support the clinical study of metformin in people without DM but with high risk of AS (115, 116).